Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18838118 | 0.88 | CYP11B1 (0.45) | LMNAP2RX3HSP90AA1POLBHSP90AB1 | |
| SCHEMBL18838115 | 0.75 | SMN1; SMN2 (0.44) | ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6599385 | 0.71 | CYP11B1 (0.48) | HSP90AA1HSP90AB1THRB | |
| Hydrochloric Acid SCHEMBL6600884 | 0.70 | CYP11B1 (0.40) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL21339995 | 0.69 | HDAC6 (0.56) | LMNAPOLBMAPTALDH1A1KDM4E | |
| SCHEMBL2467025 | 0.68 | SRC (0.37) | LMNAMAPTALDH1A1HTTKDM4E | |
| SCHEMBL18838185 | 0.68 | RAB9A (0.48) | LMNAPOLBMAPTALDH1A1HTT | |
| SCHEMBL16841638 | 0.67 | CYP11B1 (0.52) | HSP90AA1HSP90AB1MAPTALDH1A1KDM4E | |
| SCHEMBL16199218 | 0.65 | LMNA (0.70) | LMNAPOLBMAPTALDH1A1KDM4E | |
| SCHEMBL3911396 | 0.65 | TP53 (0.53) | LMNAPOLBMAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3374350-B1 | HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | FORGE THERAPEUTICS INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210078957-A1 | SUBSTITUTED PYRIMIDINES FOR TREATING BACTERIAL INFECTIONS | FORGE THERAPEUTICS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10875832-B2 | Substituted pyrimidines for treating bacterial infections | FORGE THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10414735-B2 | Substituted hydroxypyrimidinones for treating bacterial infections | FORGE THERAPEUTICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078957-A1 | SUBSTITUTED PYRIMIDINES FOR TREATING BACTERIAL INFECTIONS | DPYD, TYMP, UMPS | LMNA 4118/4885P2RX3 284/4885HSP90AA1 1692/4885 |
| US-10414735-B2 | Substituted hydroxypyrimidinones for treating bacterial infections | ALPI, HPGDS, SDHB | LMNA 4193/4885P2RX3 1182/4885HSP90AA1 347/4885 |
| US-10875832-B2 | Substituted pyrimidines for treating bacterial infections | UMPS, DPYD, TYMP | LMNA 4080/4885P2RX3 196/4885HSP90AA1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.